ICON plc Announces Upcoming Webinar on Immunotherapy Development
ICON plc has scheduled a live webinar titled 'De-Risking Immunotherapy Development: 5 Key Early Decisions' for December 7, 2026.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
ICON plc has scheduled a live webinar titled 'De-Risking Immunotherapy Development: 5 Key Early Decisions' for December 7, 2026.
Following the company's Q3 2026 earnings call, multiple financial institutions including Deutsche Bank, RBC, and Truist Securities have updated their price targets for ICON.
Icon (NASDAQ:ICLR) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For
The global rare disease CRO market is projected to grow from $2.07 billion in 2025 to $3.16 billion by 2030, with an 8.9% CAGR. Growth is driven by expanding gene and cell therapy pipelines, increasing orphan drug approvals, precision medicine adoption, and decentralized clinical trials. Key trends include AI integration, patient registries, and real-world evidence utilization.
Citigroup analyst Albert Hu maintains Icon (NASDAQ:ICLR) with a Neutral and lowers the price target from $180 to $175.